CTLA4 and uveitis: showed half of their ICI-associated uveitis cases occurred with nivolumab (an anti-PD-1 class of ICI) monotherapy (32% of total cases) or ipilimumab/nivolumab (anti-CTLA-4 and anti-PD1 class of ICI) (28% of total cases) combination (22).